Recent advancements include novel antibody–drug conjugate (ADC) designs targeting diverse antigens, such as HER2, HER3, and CD276, demonstrating potent anti-tumor activity and improved strategies for drug delivery. This evidence concerns the gene ERBB3 and neoplasm.